PF-Atlas › Clinical Trials › NCT02138825

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias

Riociguat · Phase 2

Registry ID

NCT02138825

Phase

Phase 2

Status

Terminated

Drug / intervention

Riociguat (Adempas, BAY63-2521)

Sponsor

Bayer

Start

2014-06-04

Enrollment

147

Locations

About this trial

To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).

View NCT02138825 on ClinicalTrials.gov →

Explore related

All Riociguat trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02138825 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.